Wall Street expects a year-over-year increase in earnings on higher revenues when Equifax (EFX) reports results for the quarter ended September 2025. While this widely-known consensus outlook is ...
(RTTNews) - Akero Therapeutics (AKRO) unveiled new data from its Phase 2b SYMMETRY trial highlighting the potential of efruxifermin - EFX to reverse fibrosis in patients with compensated cirrhosis (F4 ...
In trading on Friday, shares of Equifax Inc (Symbol: EFX) crossed above their 200 day moving average of $254.15, changing hands as high as $257.21 per share. Equifax Inc shares are currently trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback